Fractional retention of technetium-99m-sestamibi as an index of P- glycoprotein expression in untreated breast cancer patients

Journal of Nuclear Medicine

Volumn 38, Issue 9, 1997, Pages 1348-1351

  Del Vecchio, Silvana ^a   Ciarmiello, Andrea ^b   Pace, Leonardo ^b   Potena, Maria I ^b   Carriero, Maria V ^b   Mainolfi, Ciro ^b   Thomas, Renato ^b   D'Aiuto, Giuseppe ^b   Tsuruo, Takashi ^b   Salvatore, Marco ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b NONE

Author keywords

Breast carcinoma; Multidrug resistance; P glycoprotein; Technetium 99m sestamibi

Indexed keywords

GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MRK 16; UNCLASSIFIED DRUG;

ARTICLE; AUTORADIOGRAPHY; BREAST CANCER; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOISOTOPE DISTRIBUTION;

AUTORADIOGRAPHY; BREAST NEOPLASMS; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM PROTEINS; P-GLYCOPROTEIN; RISK FACTORS; TECHNETIUM TC 99M SESTAMIBI;

EID: 0030884251     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Gottesman MM. How cancer cells evade chemotherapy: 16th Richard and Hinda Rosenthal foundation award lecture. Cancer Res 1993;53:747-754.
2. Chin KV, Pastan I, Gottesman MM. Function and regulation of the human multidrug-resistance gene. Adv Cancer Res 1993;60:157-180.
3. Van der Bliek AM, Borst P. Multidrug resistance. Adv Cancer Res 1989;52:165-202.
4. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987;84:265-269.
5. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-7738.
6. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug-resistance gene in human cancers. J Natl Cancer Inst 1989;81:116-124.
7. Weinstein RS, Hansen KK, McBeath RB, Dalton WS. Expression of the MDR1 gene (P-glycoprotein) in breast cancer. Recent Results Cancer Res 1993;127:49-54.
8. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993;53:977-984.
9. Wackers FJT, Berman DS, Maddahi J, et al. Technetium-99m-hexakis 2-methoxy isobutylisonitrile: human biodistribution, dosimetry, safety and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 1989;30:301-311.
10. 99mTc-hexakis 2-methoxy isobutylisonitrile in benign and malignant lesions of the lungs. Clin Nucl Med 1989;14:333-340.
11. 99mTc-MDP. J Nucl Med 1992;33:319-324.
12. 99mTc-sestamibi in tumor imaging. In: Freeman LM, ed. Nuclear medicine annual 1994. New York: Raven Press Ltd; 1994:181-234.
13. Khalkhali I, Mena I, Diggles L. Review of imaging techniques for the diagnosis of breast cancer: a new role of prone scintimammography using technetium-99m-sestamibi. Eur J Nucl Med 1994;21:357-362.
14. Khalkhali I, Cutrone J, Mena I, et al. Technetium-99m-sestamibi scintimammography of breast lesions: clinical and pathological follow-up. J Nucl Med 1995;36:1784-1789.
15. Palmedo H, Schonburg A, Grunwald F, Mallmann P, Krebs D, Biersack HJ. Technetium-99m-MIBI scintimammography for suspicious breast lesions. J Nucl Med 1996;37:626-630.
16. Villanueva-Meyer J, Leonard MH Jr, Briscoe E, et al. Mammoscintigraphy with technetium-99m-sestamibi in suspected breast cancer. J Nucl Med 1996;37:926-930.
17. Duran Cordobes M, Starzec A, Delmon-Moingeon L, et al. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression. J Nucl Med 1996;37:286-289.
18. 99mTc-sestamibi scan in untreated breast cancer patients. Eur J Nucl Med 1997; 24:150-159.
19. Hartmann WH, Ozzello L, Sobun LH, Stalsberg H. Histological typing of breast tumors, 2nd ed. Geneva: WHO; 1981.
20. Hamada H, Tsuruo T. Functional role for the 170-to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 1986;83:7785-7789.
21. Georges E, Tsuruo T, Ling V. Topology of P-glycoprotein as determined by epitope mapping of MRK16 monoclonal antibody. J Biol Chem 1993;268:1792-1798.
22. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984;72:77-89.
23. r 97,000 and 250,000 protein antigen concentration in sections of human melanoma using in vitro quantitative autoradiography. Cancer Res 1988;48:5475-5481.
24. Li PY, Del Vecchio S, Fonti R, et al. Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography. J Nucl Med 1996;37:665-672.
25. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. Histochem Cytochem 1981;29:577-580.
26. Ballinger JR, Hua HA, Berry BW, Firby P, Boxen I. Technetium-99m-sestamibi as an agent for imaging P-glycoprotein-mediated multidrug resistance: in vitro and in vivo studies in a rat breast tumor cell line and its doxorubicin-resistant variant. Nucl Med Commun 1995;16:253-257.
27. Delmon-Moingeon LI, Piwnica-Worms D, Van den Abbeele AD, Holman BL, Davison A, Jones AG. Uptake of the cation hexakis (2-methoxyisobutyl-isonitrile)-technetium-99m by human carcinoma cell lines in vitro. Cancer Res 1990;50:2198-2202.
28. Schneider J, Bak M, Efferth T, Kaufmann M, Mattern J, Volm M. P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 1989;60:815-818.
29. Leonardo E, Valente G, Cappia S, et al. Immunohistochemical evaluation of P-glycoprotein in human malignancies by monoclonal antibody MC57. Int J Cancer 1994;57:841-846.
30. Charpin C, Vielh P, Duffaud F, et al. Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and immunohistochemical prognostic indicators. J Natl Cancer Inst 1994;86:1539-1545.
31. Verrelle P, Meissonnier F, Fonck Y, et al. Clinical relevance of immunohistochemical detection of multidrug-resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 1991;83:111-116.